期刊文献+

氨溴索对呼吸系统的保护机制及临床应用 被引量:4

原文传递
导出
摘要 氨溴索(ambrox01)是一种祛痰药。其化学名为:反式4-[(2-氨基3.5-二溴苄基)氨基]环已醇。近年来的研究发现,氨溴索除了具有溶解黏痰、促进痰液排出的作用、增加肺泡表面活性物质的生成外,还具有抗炎、抗氧化,增加抗菌药在肺组织中的浓度等作用。现就近年来氨溴索对呼吸系统的保护机制及其临床应用作一综述。
出处 《药物流行病学杂志》 CAS 2011年第9期494-496,共3页 Chinese Journal of Pharmacoepidemiology
  • 相关文献

参考文献21

  • 1Beeh KM, Beier J, Esperester A, et al. Antiinflammatory properties of ambroxol[J]. Eur J Med Res, 2008, 13 : 557- 562.
  • 2Bianchi M, Mantovani A, Erroi A, et al. Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells[ J]. Agents Actions, 1990, 31:275-279.
  • 3Pfeifer S, Zissel G, Kienest K, et al. Reduction of cytokine release of blood and broncho-alveolar mononuclear cells by ambroxol [ J ]. Eur J Med Res, 1997, 2 : 129-132.
  • 4金晓光,张洪玉,邝土光,庞宝森,牛淑洁,张杰,王辰,翁心植.氨溴索对低氧性肺动脉高压大鼠部分细胞因子的影响[J].中华内科杂志,2003,42(7):504-505. 被引量:6
  • 5Sorensena GL, Husbyb S, Holmskov U. Surfaetant protein A and surfactant protein D variation in pulmonary disease [J]. Immunobiology, 2007, 212:381-416.
  • 6马玉腾,田英平,苏建玲,石汉文,吕翠环,孙志平,刘建辉,冯丽.氨溴索对百草枯中毒大鼠肺组织损伤及肺表面活性蛋白-A的影响[J].中华劳动卫生职业病杂志,2006,24(6):348-351. 被引量:59
  • 7Seifart C, Clostermann U, Seifart U, et al. Cell-specific modulation of surfactant proteins by ambroxol treatment [ J ]. Toxicol Appl Pharmaco, 2005, 203( 1 ) :27-35.
  • 8Stetinova V, Herout V, Kvetina J. In vitro and in vivo an- tioxidant activity of ambroxol [ J ]. Clin Exp Med, 2004, 4 (3) :152-158.
  • 9Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy [ J 1- Respir Med, 1998, 92(4) :609-623.
  • 10赵双平,郭曲练,王瑞珂,王锷.沐舒坦对盐酸吸入后大鼠氧化抗氧化系统的影响[J].中南大学学报(医学版),2004,29(5):586-588. 被引量:6

二级参考文献52

  • 1缪昌东,赵小兰,张德坤,张洵,徐国权,陈杰.板式抗结核组合药物不良反应调查[J].中国防痨杂志,2008,30(1):67-68. 被引量:14
  • 2蔡长清,毛红,王宝香,高明.氨溴索对氨苄西林/舒巴坦的肺运转作用在儿科中的运用[J].中国抗生素杂志,2005,30(8):509-511. 被引量:11
  • 3李莉.氨溴索佐治慢性喘息性支气管炎急发疗效观察[J].临床肺科杂志,2007,12(1):36-37. 被引量:35
  • 4aRobert MJ, Jussi JS, Henry MB, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial [J]. Ann Intern Med,2002,137(8):640-647.
  • 5McNeill L, Alien M, Estrada C, et al. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis- improved completion rates but more hepatotoxicity[J]. Chest, 2003,123(1) : 102-106.
  • 6Malerba M,Ragnoli B. Ambroxol in the 21st century : pharmacological and update[J]. Expert Opin Drug Metab Toxicol, 2008,4(8) : 1119.
  • 7Su X, Wang L, Song Y, et al. Inhibition of inflammatory responses by ambroxol,a mucolytic agent, in a murine model of acute pulmonary injury induced by lipopolysaccharride[J]. Intesive Care Med, 2004,30( 1 ) : 133 140.
  • 8[1]Hudson LD,Milberg JA,Anardi D,et al.Clinical risks for development of the acute respiratory distress syndrome [J].Am J Respir Crit Care Med,1995,151(2 pt 1):293-301.
  • 9[2]Teramoto S,Suzuki M,Ohga E,et al.Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary diseases [J].Pharmacology,1999, 59(3):135-141.
  • 10[3]Gillissen A, Bartling A, Schoen S, et al. Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro [J]. Lung, 1997, 175(4):235-242.

共引文献205

同被引文献34

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部